We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT05395858
Previous Study | Return to List | Next Study

A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers (REAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05395858
Recruitment Status : Recruiting
First Posted : May 27, 2022
Last Update Posted : March 10, 2023
Information provided by (Responsible Party):

Brief Summary:

People with hemophilia A do not have enough of a protein found naturally in the blood called "clotting factor 8", also known as FVIII. This protein helps the blood to clump together to prevent and stop bleeding. People with lower levels of FVIII or FVIII that does not work properly may bleed for a long time from minor wounds, bleed into their joints, or have internal bleeding.

The study treatment, Jivi (also called damoctocog alfa pegol), is already available as a treatment for people aged 12 years and older with hemophilia A, to help prevent bleeding, also known as "prophylactic" treatment. It works by replacing the missing FVIII, or the FVIII that does not work properly. It can also be used to stop bleeding that has already occurred and prior to surgery to prevent bleeding.

The main goal of this study is to learn how damoctocog alfa pegol is used in the "real world" as a treatment in the United States (US) and how well it works and what other treatments patients use while receiving damoctocog alfa pegol treatment. It will also determine how satisfied people are with the treatment. There will be no required visits with a study doctor in this study.

The study will include about 20 male or female patients in the US aged 12 years and over who have hemophilia A. All the patients in this study will have switched from their previous FVIII replacement treatment to damoctocog alfa pegol. While the patients are receiving damoctocog alfa pegol, they will complete a survey to say how they feel about the treatment. Their doctors will also record information about their treatment with damoctocog alfa pegol and how well it is working.

This study will collect information from the patients' medical records and surveys. They will use this information to find out more about treatment with damoctocog alfa pegol under "real world" conditions. They will look at:

  • how often the patients receive damoctocog alfa pegol and how much they use
  • what other treatments the patients received before receiving damoctocog alfa pegol, how they used it and how much they used
  • how well damoctocog alfa pegol works at preventing bleeding, and how it compares to previous products used.

Condition or disease Intervention/treatment
Hemophilia A Other: No intervention

Layout table for study information
Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: REAL: A Pre-/Post-Intervention Descriptive Analysis and Cross-Sectional Survey to Evaluate Real-World Treatment Outcomes, Consumption, and Satisfaction With Damoctocog Alfa Pegol in US Hemophilia Treatment Centers
Actual Study Start Date : January 17, 2023
Estimated Primary Completion Date : June 16, 2023
Estimated Study Completion Date : June 16, 2023

Group/Cohort Intervention/treatment
Hemophilia A patients
Patients will be identified via standard medical charts or electronic medical records (EMRs).
Other: No intervention
Retrospective analysis using database without any intervention assigned in the study.

Primary Outcome Measures :
  1. Frequency of damoctocog alfa pegol infusions [ Time Frame: From index date through the date of central IRB approval (3 years and 8 months) ]
    Reported as infusions. IRB: institutional review board

Secondary Outcome Measures :
  1. Descriptive summary of pre-damoctocog alfa pegol treatment regimen [ Time Frame: 6 months prior to the index date. ]
  2. Descriptive summary of damoctocog alfa pegol treatment regimen. [ Time Frame: Up to 5 years from index date ]
  3. Descriptive summary of post-damoctocog alfa pegol treatment regimen, if applicable. [ Time Frame: Up to 4 years ]
    Only applicable for patients who discontinue damoctocog alfa pegol treatment regime.

  4. Descriptive summary of changes in pre-damoctocog alfa pegol treatment regimes [ Time Frame: 6 months prior to the index date. ]
  5. Descriptive summary for reasons for treatment discontinuation of pre-damoctocog alfa pegol treatment regimes. [ Time Frame: 6 months prior to the index date. ]
  6. Annualized number of spontaneous, joint, and trauma bleeds before initiation of treatment with damoctocog alfa pegol. [ Time Frame: 6 months prior to the index date. ]
  7. Annualized number of spontaneous, joint, and trauma bleeds post initiation of treatment with damoctocog alfa pegol. [ Time Frame: Up to 5 years from index date ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
United States patients aged ≥12 years diagnosed with hemophilia A (congenital FVIII deficiency) who switched from a previous FVIII replacement treatment to damoctocog alfa pegol. No investigational products will be administered in this study.

Inclusion Criteria:

  • Male or female with a diagnosis of hemophilia A
  • Previously or currently treated with damoctocog alfa pegol for at least 6 months.
  • Treated with damoctocog alfa pegol per the US approved label to include:

    • Aged ≥12 years at the time of damoctocog alfa pegol treatment initiation
    • Previously treated for hemophilia A with an FVIII replacement therapy other than damoctocog alfa pegol
    • Treatment modality of on-demand, prophylactic, intermittent prophylaxis or a combination thereof
  • Have data in the medical record at the participating site as follows:

    • For a minimum of 6 months prior to the damoctocog alfa pegol initiation date
    • For a minimum of 6 months post-damoctocog alfa pegol initiation date AND the patient was receiving treatment with damoctocog alfa pegol during this 6-month follow-up period AND this data is dated prior to the central institutional review board (IRB) approval date for the study
    • To include the FVIII replacement therapy most recently received prior to the initiation of damoctocog alfa pegol
  • For patients in the prospective cohort

    • Signed informed consent
    • Current treatment with damoctocog alfa pegol or discontinued use of damoctocog alfa pegol within 3 months prior to the date of enrollment into the retrospective cohort.

Exclusion Criteria:

  • Diagnosis of any other bleeding/coagulation disorder other than hemophilia A.
  • Participation in any past or current damoctocog alfa pegol interventional trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05395858

Layout table for location contacts
Contact: Bayer Clinical Trials Contact (+)1-888-84 22937 clinical-trials-contact@bayer.com

Layout table for location information
United States, California
University of California, Davis Not yet recruiting
Sacramento, California, United States, 95817
United States, Louisiana
Tulane University Recruiting
New Orleans, Louisiana, United States, 70112
United States, Minnesota
Regents of the University of Minnesota Not yet recruiting
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Additional Information:
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT05395858    
Other Study ID Numbers: 21280
First Posted: May 27, 2022    Key Record Dates
Last Update Posted: March 10, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description:

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Bleeding disorder
Coagulation factor VIII
Blood Coagulation Disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn